Previous 10 | Next 10 |
– Continue to advance and expand opportunities with established diversified development pipeline – Company ended the year with $65.3 million in cash, expected to fund operations through 2023 TORONTO, ONTARIO, March 29, 2022 (GLOBE NEWSWIRE) -- Aeterna...
Aeterna Zentaris (NASDAQ:AEZS) said that enrollment of a phase 3 trial of macimorelin in childhood-onset growth hormone deficiency is delayed due to ongoing impacts from COVID-19 and the situation between Ukraine and Russia. The company said that recruitment of the AEZS-130-P02 trial "may now...
– Company actively monitoring delays to mitigate potential impact of COVID-19 and conflict in Ukraine following Russian invasion on the estimated completion dates for the trial – Patient enrollment expected to continue into 2023 TO...
Aeterna Zentaris (NASDAQ:AEZS) expanded its existing research program with the Julius-Maximilians-University Wuerzburg (JMU) on the development of COVID-19 and Chlamydia trachomatis vaccines. The expanded research activities will use JMU’s program involving 3D models of human intestina...
– R esearch agreement expanded for development of human 3D intestinal tissue models to study Salmonella enterica pathogenesis TORONTO, ONTARIO, March 10, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or ...
Aeterna Zentaris (AEZS +7.7%) said its licensor, The University of Sheffield received a notice of allowance from the U.S. Patent and Trademark Office (USPTO). The patent application No. 16/608,611, entitled, “Parathyroid Hormone Fusion Polypeptide” includes claims...
– Notice of allowance received by Company’s l icensor, The University of Sheffield (UK) bolsters intellectual property of AEZS-150 in development for the potential treatment of chronic hypoparathyroidism – TORONTO, ONTARIO, Marc...
CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic pr...
– Company advancing diversified portfolio focused on areas of significant unmet medical need – Supported by solid financial position with cash to fund operations beyond 2023 TORONTO, ONTARIO, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ...
– Live video webcast presentation on Wednesday, January 26 th at 9:00 AM ET CHARLESTON, S.C., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharma...
News, Short Squeeze, Breakout and More Instantly...
Aeterna Zentaris Inc. Company Name:
AEZS Stock Symbol:
NASDAQ Market:
Aeterna Zentaris Inc. Website:
2024-07-17 19:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for he...
Aeterna Zentaris Inc. (NASDAQ: AEZS) is one of today's top gainers. The company's shares have moved 24.97% on the day to $6.7. Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimore...